Status:
COMPLETED
Safety, Tolerability and Relative Bioavailability of Pegvisomant in Healthy Subjects
Lead Sponsor:
Pfizer
Conditions:
Bioavailability
Eligibility:
All Genders
21-55 years
Phase:
PHASE1
Brief Summary
The hypothesis to be tested is that the bioavailability of the new 30-mg vial is similar to that of the current approved 15 -mg vials. In addition, the SC injection using the new 30-mg vial is safe an...
Eligibility Criteria
Inclusion
- Healthy males or females between the ages of 21 and 55 years
Exclusion
- Positive urine drug screen
- Excessive use of alcohol or nicotine-containing products
- Pregnant or nursing females
Key Trial Info
Start Date :
October 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2011
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT01181973
Start Date
October 1 2010
End Date
January 1 2011
Last Update
January 5 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Singapore, Singapore, 188770